Anti-TNFR2 mAb BCG003

A non-blocking anti-human TNFR2 antibody (BCG003) was generated from RenMab™ mice (humanized IgG mice), which is a highly effective platform for fully human antibody generation. Our data demonstrates that BCG003 is a novel anti-TNFR2 antibody with potential for anti-tumor immunotherapy.

Download Brochure Request a Quote

on this page

  • Highlights of anti-TNFR2 mAb
  • About TNFR2

Posters

View All
    Highlights of anti-TNFR2 mAb
    • BCG003 binds to the CRD3 and CRD4 domains of TNFR2 without blocking the binding of TNFα.
    • In vitro, BCG003 stimulates the proliferation and activation of hCD8+ T cells, displays ADCC effects on TNFR2–positive cells, and reverses Treg suppression of CD8+ cell proliferation.
    • BCG003 monotherapy demonstrates anti-tumor activity and enhances tumor inhibition efficacy in combination with anti-PD-1/PD-L1 antibodies. No toxicity was observed in hTNFR2 mice.
    • Nonclinical toxicological pharmacokinetics studies in cynomolgus monkeys are ongoing, and preliminary data suggest good PK and tolerance of BCG003 in cynomolgus monkeys.
    Treatment with BCG003 reduced tumor volumes in multiple tumor models
    Treatment of BCG003 enhanced the efficacy of PD-1/PD-L1 blockade in MC38 model
    About TNFR2

    Tumor necrosis factor receptor-2 (TNFR2) is selectively highly expressed on immune cells and some tumor cells, which mediates the signaling of immune stimulation and survival, which result in cell activation, migration and proliferation. Research indicates that TNFR2 plays an important role in tumor immune escape and tumor growth.

    Previous research has showned that TNFR2 antibody is as effective as PD-1 antibody. In addition, TNFR2 antibody also has anti-tumor effect in PD-1 resistant tumor models and the effect is even stronger when two drugs combined. Therefore, TNFR2 has become a next generation cancer therapy.

    So far, the research and development of drugs targeting TNFR2 is still at an early stage worldwide. There is no such product on the market yet. Most pipeline assets are at preclinical stage and the fastest at clinical phase 1/2a.

    Learn more about the RenLite and ADC platform.